J&J acquires Firefly

J&J to Acquire Cancer Drug Technology Developer Firefly Bio for $1 Billion

Johnson & Johnson agreed to acquire Firefly Bio for $1 billion to bolster its oncology pipeline with Firefly's Firelink platform. The technology targets KRAS-driven cancers, offering potential treatme